Two small errors were found in the figures of this paper. The first was in Figure 1A: where the cell name “GIIS-882T” was incorrect, and secondly, in Figure 4C: the Hoechest 3344 image of the imatinib group in GIST1 cells was not consistent with the EDU and Merge. We revised the cell name “GIIS-882T” to “GIST-882” in Figure 1A. We also have accordingly corrected and replaced the panel in Figure 4C with the image of Hoechest 3344 of the imatinib group in GIST1 cells. Changes in representative images do not affect the interpretation of Figure 1A or Figure 4C. These errors have no bearings on the interpretation of the results, nor do they influence the conclusions of the work. We apologize for these mistakes. The corrected figures are as follows.
Figure 1.
CCDC26 expression in GIST cells and its relationship with imatinib sensitivity. A: Real-time PCR detection of CCDC26 expression in GIST cell lines. B: CCK-8 assay of GIST cell viability in the presence of imatinib (0, 20, 40, 60, 80 μM). C, D: GIST cell viability in the presence of IC50 of imatinib (GIST-882, 56.06 μM; GIST-T1, 41.08 μM) for 0 h, 6 h, 24 h, and 48 h (**P < 0.01).
Figure 4.
Effect of c-KIT on GIST cell viability, proliferation, and apoptosis in vitro. A, B: CCK-8 assay of the viability of GIST cells treated with c-KIT siRNA, Negative siRNA, or Control in the presence of imatinib (0, 20, 40, 60, 80 μM). C, D: EdU assay of cell proliferation rate under IC50 of imatinib in GIST cells treated with c-KIT siRNA or control siRNA. The number of EDU-positive cells was counted. E: Flow cytometry analysis of apoptosis in GIST cells transfected with control siRNA or CCDC26 siRNA (*P < 0.05).